Evaluating the in vitro activity of cefoperazone-sulbactam against Gram negative pathogens in blood stream infections using automated systems

Uksim  Qadri; Sofiya  Zaffar; Saleem Javaid  Wani; Shugufta  Roohi; Munazah  Aman; Sabah  Bhat; Umaya  Majid

doi:10.18502/ijm.v16i6.17245

Uksim Qadri Department of Microbiology, Sher-i-Kashmir Institute of Medical Sciences, Jammu and Kashmir, India
Sofiya Zaffar Department of Microbiology, Sher-i-Kashmir Institute of Medical Sciences, Jammu and Kashmir, India
Saleem Javaid Wani Department of General Medicine, Sher-i-Kashmir Institute of Medical Sciences, Jammu and Kashmir, India
Shugufta Roohi Department of Microbiology, Sher-i-Kashmir Institute of Medical Sciences, Jammu and Kashmir, India
Munazah Aman Department of Microbiology, Sher-i-Kashmir Institute of Medical Sciences, Jammu and Kashmir, India
Sabah Bhat Department of Microbiology, Sher-i-Kashmir Institute of Medical Sciences, Jammu and Kashmir, India
Umaya Majid Department of Microbiology, Sher-i-Kashmir Institute of Medical Sciences, Jammu and Kashmir, India

DOI: https://doi.org/10.18502/ijm.v16i6.17245

Keywords: Antimicrobial resistance; Cefoperazone/sulbactam; Gram negative isolates

Abstract

Background and Objectives: The incidence of multidrug-resistant, Gram-negative organisms, isolated as the etiological agents of infections is ascending. The advent of novel antibiotics poses significant challenges, necessitating the optimization and utilization of extant antimicrobial agents. Cefoperazone, a third-generation cephalosporin and β-lactam antimicrobial, when combined with sulbactam, an irreversible β-lactamase inhibitor, mitigates the vulnerability of cefoperazone to β-lact- amase-producing organisms. Nonetheless, regional data on the susceptibility patterns for this pharmacological combination remains scarce. The primary objective of this investigation was to assess the efficacy of the cefoperazone-sulbactam combi- nation against prevalent Gram-negative bacteria isolated from blood cultures.

Materials and Methods: A total of 700 Gram-negative isolates, comprising Escherichia coli, Klebsiella pneumoniae, Acine- tobacter species, and Pseudomonas aeruginosa, were procured using the BacT/Alert 3D system. The identification and sus- ceptibility testing for cefoperazone-sulbactam were performed using the VITEK Compact ID and AST system. Comparative analysis was conducted against other tested antibiotics.

Results: The study revealed that cefoperazone-sulbactam exhibited commendable in-vitro activity against Gram-negative pathogens isolated from blood, surpassed only by colistin and tigecycline.

Conclusion: Cefoperazone-sulbactam demonstrates robust activity against the most frequently encountered clinical patho- gens, suggesting its potential as an efficacious therapeutic agent. The findings underscore the imperative for ongoing surveil- lance of resistance patterns and trends among commonly used antimicrobials.